Perspectivas del mercado y visión del analista:
El tamaño del mercado de terapias contra el cáncer de próstata se está expandiendo con el aumento de las actividades de I+D para introducir nuevos compuestos farmacológicos y el aumento del número de tratamientos para el cáncer de próstata. casos de cáncer y el creciente apoyo gubernamental al diagnóstico del cáncer de próstata. Además, la disponibilidad de productos avanzados por parte de los actores del mercado impulsa el crecimiento del mercado. En enero de 2023, BDR Pharmaceutical lanzó una versión genérica de apalutamida que se utiliza para tratar el cáncer de próstata en la India. El medicamento se lanza bajo la marca APATIDE y se receta para tratar el cáncer de próstata no metastásico resistente a la castración y el cáncer de próstata metastásico sensible a la castración.
Impulsores y desafíos del crecimiento:
El cáncer de próstata es uno de los problemas de salud más comunes en hombres, especialmente en hombres mayores de 50 años o más. El cáncer de próstata es principalmente común en hombres obesos y con antecedentes familiares de cáncer de próstata. El cáncer de próstata es una amenaza silenciosa, ya que a menudo se desarrolla sin síntomas perceptibles. Por tanto, la detección temprana de este cáncer no es tan fácil. La mayoría de los cánceres de próstata se originan en la región periférica de la glándula prostática. Para que los síntomas se vuelvan evidentes, el cáncer debe alcanzar un tamaño en el que ejerza presión sobre la uretra, o el dolor óseo debido a la metástasis podría ser el síntoma inicial de presentación del cáncer de próstata avanzado en algunos casos. Sin embargo, cualquier persona de 50 años o más que presente síntomas del tracto urinario inferior, disfunción eréctil o hematuria debe considerar la posibilidad de cáncer de próstata. El cáncer de próstata es la quinta causa de muerte por cáncer entre los hombres en todo el mundo y el segundo cáncer más comúnmente diagnosticado. Incluso si ha habido una disminución en la incidencia del cáncer de próstata desde 2000, hay un aumento en la incidencia del cáncer de próstata en etapa avanzada a partir de 2010. Las tasas de incidencia y mortalidad del cáncer de próstata difieren mucho. Los países desarrollados generalmente tienen una mayor incidencia de cáncer de próstata pero una menor mortalidad. El riesgo de cáncer de próstata en Estados Unidos es casi cuatro veces mayor que el riesgo global. Según Novartis AG, en 2020 se notificaron ~1,4 millones de nuevos casos de cáncer de próstata y alrededor de 375.000 muertes por cáncer de próstata en todo el mundo. El creciente número de casos de cáncer de próstata en todo el mundo y la baja tasa de detección del cáncer de próstata impulsan el crecimiento del mercado de terapias contra el cáncer de próstata.
Perspectivas estratégicas
Segmentación y alcance del informe:
El mercado de terapias contra el cáncer de próstata está segmentado según la terapia tipo, usuario final y geografía. El mercado de terapias contra el cáncer de próstata, por tipo de terapia, se segmenta en terapia hormonal, quimioterapia, inmunoterapia, terapia dirigida y otras. El mercado de terapias contra el cáncer de próstata, por usuario final, se segmenta en hospitales, clínicas especializadas y otros. Según la geografía, el mercado de terapias contra el cáncer de próstata está segmentado en América del Norte (EE. UU., Canadá y México), Europa (Reino Unido, Alemania, Francia, Italia, España y el resto de Europa), Asia Pacífico (China, Japón). , India, Corea del Sur, Australia y el resto de Asia Pacífico), Medio Oriente y África (EAU, Arabia Saudita, Sudáfrica y el resto de Medio Oriente y África) y América del Sur y Central (Brasil, Argentina , y el resto de América del Sur y Central).
Análisis segmentario:
El mercado de terapias contra el cáncer de próstata, por tipo de terapia, se segmenta en terapia hormonal, quimioterapia, inmunoterapia, terapia dirigida y otras. En 2022, el segmento de terapia hormonal tuvo la mayor participación de mercado después de la quimioterapia, y se espera que el mismo segmento registre la CAGR más alta de 2022 a 2030. La quimioterapia se considera un tratamiento importante para el cáncer de próstata. En esta terapia, los medicamentos destruyen las células cancerosas nuevas o existentes en los pulmones. La quimioterapia para el cáncer de próstata metastásico puede aliviar los síntomas. También puede ayudar a reducir el cáncer y mejorar la calidad de vida. Docetaxel (Taxotere) se considera el estándar de atención en la quimioterapia del cáncer de próstata en pacientes resistentes a la terapia hormonal. La FDA también aprobó el fármaco de quimioterapia cabazitaxel (Jevtana) para tratar el cáncer de próstata resistente a la castración. También se utiliza para pacientes afectados por cáncer de próstata metastásico que ha crecido mientras tomaban docetaxel.
Mercado de terapias contra el cáncer de próstata, por usuario final – 2022 y 2030
Análisis regional:
El mercado de terapias contra el cáncer de próstata está segmentado geográficamente en América del Norte, Europa, Asia Pacífico, Medio Oriente y África, y América del Sur y Central. América del Norte es el mayor contribuyente al crecimiento del mercado mundial de terapias contra el cáncer de próstata. Se espera que Asia Pacífico registre la CAGR más alta en el mercado de terapias contra el cáncer de próstata de 2022 a 2030. El crecimiento del mercado de terapias contra el cáncer de próstata en los EE. UU. está impulsado principalmente por la creciente incidencia de casos de cáncer de próstata, lanzamientos de productos e iniciativas gubernamentales. En junio de 2023, Lynparza (olaparib) de AstraZeneca y MSD en combinación con prednisona o prednisolona y abiraterona fue aprobado en los EE. UU. para tratar a pacientes adultos con sospecha de cáncer de próstata metastásico resistente a la castración (mCRPC) con mutación nociva de BRCA (BRCAm). Además, en noviembre de 2023, la FDA aprobó la enzalutamida, un producto fabricado por Astellas Pharma US, Inc.. El producto se utiliza para el tratamiento del cáncer de próstata no metastásico sensible a la castración (nmCSPC) con recurrencia bioquímica con alto riesgo de metástasis (BCR de alto riesgo).
Desarrollos de la industria y oportunidades futuras:
Varias iniciativas por clave Los actores que operan en el mercado de terapias contra el cáncer de próstata se enumeran a continuación:
En marzo de 2022, la FDA de EE. UU. aprobó Pluvicto (lutetium Lu 177 vipivotida tetraxetan) de Novartis para el tratamiento de pacientes adultos con un tipo de cáncer de próstata avanzado llamado antígeno de membrana específico de la próstata. Cáncer de próstata metastásico positivo resistente a la castración (mCRPC positivo para PSMA). En abril de 2023, la FDA otorgó a Lantheus Holdings Inc y POINT Biopharma Global Inc la designación de vía rápida para 177Lu-PNT2002 para el tratamiento del cáncer de próstata metastásico resistente a la castración (mCRPC). PNT2002 es una innovadora terapia radiofarmacéutica basada en 177Lu dirigida a PSMA que combina un ligando dirigido a PSMA, PSMA-I&T y 177Lu radioisótopo emisor beta sin portador añadido para el tratamiento de mCRPC. Panorama competitivo y empresas clave:
Astella Pharma Inc , Johnson & Johnson Services Inc, Eli Lilly and Company, Bayer AG, Sanofi, Merck KGaA, AstraZeneca, Novartis AG, AbbVie y Bristol Myers Squibb se encuentran entre los actores destacados que operan en el mercado de terapias contra el cáncer de próstata. Estos actores del mercado se centran en lanzamientos de nuevos productos y expansiones geográficas para satisfacer la creciente demanda de los consumidores en todo el mundo y aumentar su gama de productos en carteras especializadas. Su presencia global les permite atender a una gran base de clientes, lo que posteriormente facilita la expansión del mercado.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Prostate cancer is one of the most common health problems in men, especially in older men (aged above 50 years). Prostate cancer is mostly common in men who are obese and have a family history of prostate cancer. Prostate cancer is a silent threat that often develops without noticeable symptoms, and hence, early detection of this cancer is not that easy. Typically, the majority of prostate cancers originate in the peripheral region of the prostate gland. Consequently, for symptoms to become apparent, the cancer must reach a size where it exerts pressure on the urethra, or in some cases, bone pain from the metastasis might be the initial presenting symptom of advanced prostate cancer. However, any individual aged 50 or above who presents with lower urinary tract symptoms, erectile dysfunction, or hematuria should consider the possibility of prostate cancer.
The increasing cases of prostate cancer and strategic initiatives in prostate cancer therapeutics freezer bolster the prostate cancer therapeutics market size. However, the high cost associated with prostate cancer therapeutics hinders the growth of prostate cancer therapeutics market growth.
The prostate cancer therapeutics market majorly consists of players such Astella Pharma Inc, Johnson & Johnson Services Inc, Eli Lilly and Company, Bayer AG, Sanofi, Merck KGaA, AstraZeneca, Novartis AG, AbbVie, and Bristol Myers Squibb
The prostate cancer therapeutics market, by therapy type, is segmented into hormone therapy, chemotherapy, immunotherapy, targeted therapy, and others. In 2022, the chemotherapy segment held the largest market share, and the same segment is expected to record the highest CAGR from 2022 to 2030.
The prostate cancer therapeutics market, by end-user, is segmented into hospitals, specialty clinics, and others. In 2022, the hospital segment held the largest market share; moreover, the same segment is expected to record the highest CAGR during 2022–2030.
Based on geography, the prostate cancer therapeutics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to global prostate cancer therapeutics market growth. Asia Pacific is expected to register the highest CAGR in the prostate cancer therapeutics market from 2022 to 2030.
The List of Companies - Prostate Cancer Market
- Astella Pharma Inc
- Johnson & Johnson Services Inc
- Eli Lilly, and Company
- Bayer AG
- Sanofi
- Merck KGaA
- AstraZeneca
- Novartis AG
- AbbVie
- Bristol Myers Squibb
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Dec 2023
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2023
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Dec 2023
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Dec 2023
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2023
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Dec 2023
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Dec 2023
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Dec 2023
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)